Abbott Laboratories (ABT) Stock Forecast & Price Target

Abbott Laboratories
Bull Case

Here are some ways that investors could benefit from investing in Abbott Laboratories:

• Abbott Laboratories recently demonstrated strong fundamental performance by beating analyst expectations in its most recent earnings report, posting earnings per share of $1.31 against a consensus estimate of $1.28 and generating revenue of $12.59 billion, which represented a 13.0% year-over-year increase. This ability to consistently exceed forecasts and drive double-digit revenue growth suggests the company is effectively executing its business strategy, providing a solid foundation for potential capital appreciation for shareholders.
• The stock currently trades at $108.29, which is significantly below the consensus price target of $118.17 set by analysts who maintain a "Moderate Buy" rating. This valuation gap implies that the market may be undervaluing the company relative to its expected future earnings, offering investors a potential entry point with approximately 9% upside potential before the stock reaches its average analyst target.
• Abbott Laboratories offers a stable income stream through its dividend, which currently yields 2.28%. The company recently declared a quarterly dividend of $0.63 per share, which annualizes to $2.52, providing a reliable cash flow component to an investment portfolio. This consistent payout is attractive to income-focused investors seeking regular returns in addition to potential stock price appreciation.
• Insider confidence in the company's long-term prospects is evident from recent purchase activity, including a significant buy of 10,000 shares by Director Daniel J. Starks in April 2026 and a new position of 2,200 shares by CFO Philip P. Boudreau in March 2026. When company executives and directors use their own capital to increase their stakes, it often signals that they believe the stock is undervalued or that the company is well-positioned for future growth.
• The company maintains a conservative financial profile with a debt-to-equity ratio of 0.57 and a current ratio of 1.38, indicating it has sufficient liquid assets to cover its short-term liabilities. This financial stability reduces the risk of distress during economic downturns and provides Abbott Laboratories with the flexibility to invest in new medical technologies and acquisitions without excessive reliance on external debt.